Table 3.
Summary of clinical trials with NDV-based cellular vaccines and oncolysates
| Vaccine preparation |
Type of cancer | Type of study and patient number (n) |
Clinical outcome | Ref. |
|---|---|---|---|---|
| NDV 73T oncolysate |
Stage II and III melanoma | Phase II, n=83, historical controls |
Improved OS* | [129–131,134,142,148] |
| NDV Italien oncolysate |
Stage III melanoma | Phase II, n=24, historical controls |
No benefit | [149] |
| NDV 73T oncolysate |
Advanced renal cell carcinoma |
Phase II, n=208, historical controls |
Improved PFS* | [137] |
| NDV Ulster Whole-cell |
Colorectal cancer with liver metastases |
Phase III, n=51 Phase II, n=23 |
Improved PFS, improved OS for colon cancer subgroup |
[133,135,147] |
| NDV Ulster Whole-cell |
Resectable colorectal cancer |
Phase II, n=57, historical controls |
Improved OS | [139] |
| NDV La Sota Whole-cell |
Resectable colorectal cancer |
Phase III, n=567 | Improved OS | [144] |
| NDV Ulster Whole-cell |
Metastatic renal cell carcinoma |
Phase II, n=40, historical controls |
Improved OS | [138] |
| NDV Ulster Whole-cell |
Advanced ovarian cancer |
Phase II, n=82, historical controls |
Improved PFS | [156] |
| NDV Ulster Whole-cell |
Glioblastoma | Phase II, n=23, concurrent controls |
Improved PFS and OS | [146] |
| NDV Ulster Whole-cell |
Advanced head and neck |
Phase II, n=18, historical controls |
Improved OS | [157] |
| NDV Ulster Whole-cell |
Stage III melanoma | Phase II/III, n=29 | No benefit | [145] |
*
OS: overall survival,
*
PFS: progression-free survival